All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Ruxolitinib in combination with belumosudil for patients with treatment-refractory cGvHD
Bookmark this article
|
Treatment for patients with cGvHD beyond second-line therapy typically includes multiple agents with the aim of tapering systemic steroids.1 Both ruxolitinib and belumosudil are effective therapies that allow steroid tapering; however, data on the use of these therapies in combination are limited.1 A single-center, retrospective analysis assessed the safety and efficacy of ruxolitinib plus belumosudil in 20 treatment-refractory patients with cGvHD.1 Results from this analysis were published in Leukemia & Lymphoma by Caputo et al.1 |
| Key learnings |
| The ORR was 55%, with CR, PR, and initial PR then progression rates of 5%, 35%, and 15%, respectively. |
| Ruxolitinib plus belumosudil facilitated immunosuppressive agent tapering or discontinuation in all responders, highlighting its potential as a steroid-sparing option in refractory cGvHD management. |
| Treatment was well tolerated, with no discontinuations due to toxicity, indicating a favorable safety profile. Grade ≥3 pneumonia and viral URI were observed in 20% and 10% of patients, respectively, and there were no patients with CMV or EBV requiring treatment. |
| The combination of ruxolitinib and belumosudil was well-tolerated, delayed the need for alternative therapies, and facilitated the tapering of immunosuppressive therapies. Responses were observed in patients with progression after monotherapy with both agents, suggesting a potential synergistic effect. |
Abbreviations: cGvHD, chronic graft-versus-host disease; CMV, cytomegalovirus; CR, complete response; EBV, Epstein-Barr virus; ORR, overall response rate; PR, partial response; URI, upper respiratory infection.
- Caputo J, Peddireddi A, Bhatta S, et al. Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies. Leuk Lymphoma. 2024. Online ahead of print. DOI: 1080/10428194.2024.2409876
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox